Case Report ARTICLE
Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex
- 1Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, Netherlands
- 2CNCR, VU University Amsterdam, Amsterdam, Netherlands
- 3Department of Child Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, Netherlands
Background: Recent studies indicate excitatory GABA action in and around tubers in patients with tuberous sclerosis complex (TSC). This may contribute to recurrent seizures and behavioral problems that may be treated by agents that enhance GABAergic transmission by influencing chloride regulation.
Case presentation: Here, we used the chloride transporter antagonist bumetanide to treat a female adolescent TSC patient with refractory seizures, sensory hyper-reactivity, and a variety of repetitive and compulsive behaviors.
Methods: To evaluate the effect of bumetanide on behavior, auditory sensory processing, and hyperexcitability, we obtained questionnaire data, event-related potentials (ERP), and resting state EEG at baseline, after 3 and 6 months of treatment and after 1 month washout period.
Discussion: Six months of treatment resulted in a marked improvement in all relevant behavioral domains, as was substantiated by the parent questionnaires. In addition, resting-state electroencephalography and ERP suggested a favorable effect of bumetanide on hyperexcitability and sensory processing. These findings encourage further studies of bumetanide on neuropsychiatric outcome in TSC.
This case report describes a 20-year-old female patient with tuberous sclerosis complex (TSC) characterized by a mild mental retardation, autism spectrum disorder (ASD), focal epileptic seizures, and a wide range of disabling behavioral problems. The behavioral problems became unmanageable and she presented to our outpatient clinic for treatment possibilities. The wide range of refractory behavioral problems and previous paradoxical response to valproic acid (VPA) led to the suspicion of depolarizing GABA activity.
Treatment in TSC is mostly aimed at controlling seizures, whereas there are few treatment options for the accompanying behavioral and neuropsychiatric problems at present. Irritability, sensory arousal, repetitive behaviors, sleeping problems, and deficits in social communication are very common in patients with TSC (1) and these so-called tuberous sclerosis-associated neuropsychiatric disorders (TAND) are often extremely debilitating, although rarely treated successfully. Pharmacotherapy to reduce TAND is mostly attempted with psychostimulants such as methylphenidate or antipsychotic treatments, both of which can have serious side-effects, such as lowering the seizure threshold (2). Treatment of TAND is presumably complicated by the variability and heterogeneity of TAND (3). However, syndrome specific mechanisms such as mTOR dysregulation may be a general target to reduce TAND across the TSC population.
Indeed, mTOR inhibitors are being tested as possible treatment for a wide variety of neurological sequelae of TSC. Although promising for seizure reduction, no clear effects on behavioral outcome have yet been established (4). Recent studies have suggested another avenue for treatment of neurological problems. It has been shown that chloride homeostasis may be disrupted in and around tuber tissue in TSC as indicated by altered expression levels of the chloride cotransporters NKCC1 and KCC2 (Na–K–2Cl cotransporter isoform 1 and K–Cl cotransporter isoform 2, respectively). These disturbances could be leading to (focal) depolarizing GABA activity and, consequently, altered balance between excitation and inhibition (E/I) in these regions (5, 6). These findings suggest that the NKCC1 chloride transporter antagonist bumetanide might enhance synaptic transmission by strengthening inhibition in TSC. Indeed, Talos et al. (6) showed that excitatory GABA activity in slice preparations of human tuber tissue was effectively attenuated by bumetanide in vitro (6).
Clinical benefit of bumetanide therapy has not yet been demonstrated in TSC but has been shown to reduce core behavioral problems in ASD (7, 8). The strong association of TSC with ASD further suggests that bumetanide might be able to improve behavioral problems in TSC. Additionally, we have previously suggested that (history of) a paradoxical reaction to GABAergic drugs may be a prognostic marker of depolarizing GABA activity, suggesting bumetanide may be efficacious (9). In the current study, bumetanide was administered to a 20-year-old female with TSC and a history of paradoxical reaction to VPA. Effects on behavior and sensory processing were assessed using questionnaires and a neurophysiological test battery.
A 20-year-old female patient with TSC presented to our clinic with a long history of neurodevelopmental problems characterized by moderate mental retardation (Total IQ ~50), ASD (pervasive developmental disorder not otherwise specified) according to the DSM-IV TR (diagnostic and statistical manual of mental disorders, fourth edition, text-revision) and focal epileptic seizures. The manifestation of TAND in this patient was characterized by intellectual disability, sensory hyper-reactivity, irritability, obsessive and compulsive behaviors, behavioral rigidity, and inflexibility, accompanied by sleeping problems.
Family history showed second-degree history of ASD. Birth was complicated by meconium aspiration that resulted in several days of assisted ventilation. The first established developmental problems were motor- and speech delay at toddler age. TSC was suspected because of focal seizures from the age of 9 months, skin pigment stains, and structural anomalies on brain imaging. Genetic investigation confirmed a spontaneous deleterious mutation in the TSC1 gene. Subsequent MRI scans showed subcortical tubers and subependymal noduli in both hemispheres. Since childhood, the patient experienced focal to bilateral tonic-clonic seizures 1–2 times a year and focal seizures with behavioral arrest and automatisms 1–5 times daily. Localization of interictal epileptiform discharges was left frontally. Previous treatment with various antiepileptic drugs (AED) did not sufficiently control seizures. The patient had experienced a paradoxical response (evident increase instead of decrease of irritability and anxiety) to VPA. AED regime at time of the study consisted of oxcarbazepine monotherapy.
The previous paradoxical response to VPA and daily burden of behavioral problems and seizures led us to suspect depolarizing GABA activity. Therefore, we treated the patient with 0.5 mg bumetanide twice daily [according to Lemonnier et al. (8)] for a 6-month trial followed by a 1-month washout period to substantiate efficacy. Parents of the patient gave consent for off-label treatment. Monitoring of treatment effect included an extensive evaluation of behavioral questionnaires and EEG/event-related potentials (ERP) measurements. Blood tests and physical examinations were carried out as described previously (9). Transient hypokalemia was successfully treated with potassium supplements. Treatment did not cause other disturbances or discomfort due to diuretic effects. The patient received no concurrent therapies or interventions during the course of treatment, other than continuation of oxcarbazepine (a sodium channel inhibitor).
Clinical Global improvement (CGI) was assessed by the treating psychiatrist. Questionnaires included the Social Responsiveness Scale (SRS) (10), the Sensory Profile (SP-NL) (11), the Repetitive behavior scale-Revised (RBS-R) (12), the Aberrant behavior checklist (ABC) (13), and the Behavior rating Inventory of executive function (BRIEF) (14) and were filled in by both parents and tutor.
Auditory sensory processing was assessed using a P50 suppression task to measure sensory gating and a passive oddball paradigm to measure mismatch negativity (MMN). Both tasks originate from the Copenhagen Psychophysiological test battery (15, 16), which additionally consisted of a startle paradigm (PPI) and a selective attention task. All testing was performed with a 64 electrode BioSemi set-up according to the 10–20 system. Sampling started as soon as the paradigms were started and lasted to the end of it (continuous recording). The sample frequency was 2,048 Hz, and a low-pass setting of 1/5 of the AD rate. All stimuli were presented binaurally through tubal insert ear phones (EARtone®, Etymotic Research), by a computer running Presentation® software (Neurobehavioral Systems Inc.).
The P50 paradigm consisted of three experimental blocks, each consisting of 40 pairs of identical bursts of (1.5 ms and 80 dB) white noise, with an instantaneous rise time, an inter-stimulus interval (ISI) of 500 ms, and a fixed inter-trial interval of 10 s. The subject was asked to count the stimuli she was presented and to stay awake. The total duration of the P50 task was approximately 21 min.
The MMN paradigm consisted of 1,800 stimuli. The paradigm consisted of four types of stimuli: in 82% of the cases, a standard tone with a frequency of 1,000 Hz, intensity of 75 dB, and duration of 50 ms was presented. Within this sequence of standard stimuli, three types of deviants were presented, each with a probability of 6% and intensity of 75 dB: frequency deviants of 1,200 Hz and 50 ms, duration deviants of 1,000 Hz and 100 ms, and frequency-duration deviants of 1,200 Hz and 100 ms. The ISI was randomized between 300 and 500 ms. The subject was asked to ignore the stimuli while watching a silent movie. The total duration of the MMN task was approximately 15 min.
Analysis and processing of the EEG signal was carried out using Brain Electrical Source Analysis (BESA) software (version 5.2.4, MEGIS Software GmbH, Gräfelfing, Germany). Only data from relevant electrodes were processed and analyzed; i.e., Cz for P50 and FCz for MMN. Processing of the data started with re-sampling from the original 2,048 to 250 Hz to allow easier file handling. Second, the data were corrected for eye-artifacts by using the adaptive method of BESA. Third, the data were epoched (from 100 ms prestimulus to 400 ms post-stimulus for P50, and 900 ms post-stimulus for MMN), and corrected for movement (or other paradigm unrelated) artifacts by removing epochs that contained amplitude differences between maximum and minimum exceeding 75 µV in the relevant scoring windows. Subsequently, the data were band-pass filtered (high-pass: 1 Hz, low-pass: 70 Hz for P50, 40 Hz for MMN). For MMN, each of the three deviant types was expressed as the average ERP to the relevant deviant stimuli, subtracted with the average ERP to standard stimuli for each subject separately. Linked mastoids were used as a reference. Finally, MMN amplitudes were scored as the minimum amplitude within a window between 100 and 230 ms.
For P50 analysis, we used an average reference. P50 amplitude was defined as the largest trough to peak amplitude within an interval of 40–90 ms following the first (conditioning or “C”) stimulus in each paired click. The P50 amplitude following the second (testing or “T”) stimulus was identified as the largest trough to peak amplitude within an interval of 10 ms of the latency of the maximum P50 amplitude to the C-stimulus. P50 suppression was expressed as the ratio “T/C.”
Resting-State EEG Measurements
Resting-state EEG was measured during 3 min eyes-closed rest using BioSemi with a sampling frequency of 2,048 Hz (resampled offline to 512 Hz for analysis) with no hardware filters. Analysis was performed using the Neurophysiological Biomarker Toolbox (17). The signals were reviewed and transient artifacts were cut out. As a measure of long-range temporal correlations, we applied detrended fluctuation analysis (DFA) [see Linkenkaer-Hansen et al. (18)] to the amplitude envelop of band-pass filtered signal (FIR filter with a Blackman window, transition bandwidth 1 Hz) in the bands Alpha 8–13 and 6–13 Hz. A DFA exponent of 0.5 implies that oscillations amplitudes fluctuate in an uncorrelated fashion over time. When exponents increase from 0.5 toward 1.0, they signify increasing strength of long-range temporal correlations. Power spectral density was calculated using Welch’s method with 8 s hamming windows. Relative power was calculated as the bandwidth power normalized by the power in the 1–45 Hz band.
No significant change in seizure frequency or severity was observed. From approximately 1 month of treatment, marked improvements in social responsiveness, attention, reduced irritability, and restlessness were noted by both parents. In addition, sleep efficiency was improved. Parental observations were substantiated through questionnaires showing marked improvement in behavior following bumetanide treatment.
The greatest improvements (>50% from baseline) after 3 and 6 months of treatment were seen on (subscales of) the Sensory Profile (SP-NL), ABC, SRS, and RBS-R. In addition, improvements in behavior were also seen on the Behavior Rating Inventory Executive Function questionnaire (BRIEF) rated by the tutor of the patient. Figure 1 illustrates the most pronounced behavioral improvements, Table 1 shows the measured scores on all behavioral questionnaires at baseline, during treatment and at washout, and percentage of improvement after treatment.
Figure 1. Effect of bumetanide on behavior. (A) Total score of the social responsiveness scale is decreased by treatment with bumetanide, the effect is removed at washout. (B) Irritability, as measured by the Abberant behavior checklist subscale, is markedly decreased by bumetanide treatment. At washout, irritability increases again. (C) Repetitive behavior is decreased by bumetanide treatment, as indicated by total score on the repetitive behavior scale-revised (RBS-R). Washout again removes this effect. (D) Similarly, sensory behavior as measured by Sensory Profile subscales improves during 3 and 6 months of bumetanide. Again, washout reverses the effect.
To investigate physiological effects of treatment, we measured ERP using standard EEG paradigms of P50 suppression to assess sensory gating and a passive auditory oddball paradigm to measure mismatch negativity (MMN). In addition, we recorded resting-state EEG before and after treatment and washout. Sensory gating increased with bumetanide, followed by a decrease after washout (see Figure 2A). MMN amplitude to frequency deviants slightly increased after treatment, whereas the amplitude of duration and frequency-duration MMN slightly decreased. Again, washout appeared to reverse these effects (see Figure 2C). It should be noted that sensory gating as well as MMN were within normal ranges at baseline and during treatment (19).
Figure 2. Effect of bumetanide on event-related potentials and resting-state EEG. (A) T/C ratio illustrating sensory gating (as measured by the P50 suppression paradigm) is increased (lower T/C) after 3 and 6 months of bumetanide treatment. Washout decreases sensory gating again. (B) Average detrended fluctuation analysis (DFA) exponents at different measurement time points (median across all channels) in the extended 6–13 Hz long-range temporal correlations (DFA exponents) are strengthened after 6 months bumetanide treatment. (C) Mismatch negativity for frequency (C1), duration (C2), and frequency-duration (C3) deviant. Frequency MMN amplitude increases after 6 months treatment, duration, and frequency-duration MMN amplitude show a decrease after 6-month treatment. Washout removes this effect. Gray areas represent normal range, ±1 SD from healthy population as in Rydkjaer et al. (19). Note: for duration MMN, normal range goes up to −11.98 μV.
Power spectrum analysis of resting-state EEG showed that the peak frequency of alpha activity was around 7 Hz, which is lower than in the normal population (8–13 Hz). No pronounced effects of bumetanide on peak or alpha power were observed, although (extended) alpha power was highest after 6 months of treatment and decreased again at washout. DFA measures the strength of long-range temporal correlations (17) and has previously been coupled to changes in the excitatory/inhibitory balance (20, 21). We applied this analysis as a possible proxy of changes in overall E/I imbalances of GABAergic enhancement through bumetanide. DFA in extended alpha band (6–13 Hz) showed an increase of 0.04 (median across channels) in the DFA exponent after 6 months of bumetanide treatment and a decrease at washout (see Figure 2B). This increase in the DFA exponent is on the order of magnitude of the effects seen in other brain disorders, such as Alzheimer’s disease (22) and schizophrenia (23).
This case describes beneficial effects of treatment with bumetanide on behavior in a 20-year-old female diagnosed with TSC. This provides clinical support of preclinical studies that suggested that neuronal disinhibition (immature GABA activity) may be a mechanism contributing to TSC pathogenesis. Various domains of behavioral functioning improved during 6 months of bumetanide treatment, as indicated by both parents and scores on behavioral questionnaires rated by parents as well as the tutor of the patient.
Although this is merely a case report, some of the neurophysiological measurements appear to support a positive effect of bumetanide treatment on neuronal inhibition. Most notably, the strength of long-range temporal correlations (DFA measurement) was normalized during treatment, an effect that disappeared during the washout period. This finding is in line with suggestions of an effect of bumetanide on the excitatory/inhibitory balance, as modeling and clinical studies have shown less strong long-range temporal correlations when the E/I balance is impaired (17, 20, 22). Sensory gating and MMN also demonstrated a possible positive effect of bumetanide, although this should be interpreted with caution due to lack of experience with individual ERP assessment.
Washout measurements suggest that bumetanide did not result in continued therapeutic effects when administration ceased in this patient, as behavior and DFA (and possibly ERPs) deteriorated after discontinuation of bumetanide.
Our group previously reported effectiveness of bumetanide in a child with ASD and epilepsy with a previous paradoxical reaction to GABAergic drugs. This girl also suffered from a structural brain lesion in the temporal lobe (9). Indeed, temporal lobe epilepsy has been linked to elevated expression of the chloride importer NKCC1, the specific target of bumetanide (24). In addition, increased NKCC1 expression has been found in cortical dysplasia specimens from humans with focal epilepsy related to those found in TSC (6). The current study, therefore, provides further preliminary evidence that neuronal disinhibition constitutes a treatment target in to cortical dysgenesis-related neurodevelopmental disorders, especially when paradoxical responses to GABAergic drugs have been noted.
This case report confirms that bumetanide may be effective in reducing the high burden of behavioral problems in TSC, at least for some patients. More extensive trials are required to confirm the efficacy of bumetanide in TSC.
The patient and her parents provided verbal and written consent for publication of this case report.
CV: conception, data acquisition/collection, data analyses and interpretation of the work, drafting, and revision of the work. SS: data analyses, interpretation and revision of the work. FJ: patient supervision, interpretation, and revision of the work. KL-H, SD, BO: interpretation and revision of the work. HB: patient supervision, drafting, interpretation, and revision of the work.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors thank the patient and her parents for the compliance and detailed evaluation.
3. de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol (2015) 52(1):25–35. doi:10.1016/j.pediatrneurol.2014.10.004
5. Ruffolo G, Iyer A, Cifelli P, Roseti C, Muhlebner A, van Scheppingen J, et al. Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions. Neurobiol Dis (2016) 95:93–101. doi:10.1016/j.nbd.2016.07.014
7. Grandgeorge M, Lemonnier E, Degrez C, Jallot N. The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome. BMJ Case Rep (2014) 2014:bcr2013202092. doi:10.1136/bcr-2013-202092
8. Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry (2012) 2:e202. doi:10.1038/tp.2012.124
9. Bruining H, Passtoors L, Goriounova N, Jansen F, Hakvoort B, de Jonge M, et al. Paradoxical benzodiazepine response: a rationale for bumetanide in neurodevelopmental disorders? Pediatrics (2015) 136(2):e539–43. doi:10.1542/peds.2014-4133
10. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord (2003) 33(4):427–33. doi:10.1023/A:1025014929212
12. Lam KS, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord (2007) 37(5):855–66. doi:10.1007/s10803-006-0213-z
13. Rojahn J, Aman MG, Matson JL, Mayville E. The aberrant behavior checklist and the behavior problems inventory: convergent and divergent validity. Res Dev Disabil (2003) 24(5):391–404. doi:10.1016/S0891-4222(03)00055-6
14. Huizinga M, Smidts DP. Age-related changes in executive function: a normative study with the Dutch version of the Behavior Rating Inventory of Executive Function (BRIEF). Child Neuropsychol (2011) 17(1):51–66. doi:10.1080/09297049.2010.509715
15. Oranje B, Rasmussen H, Ebdrup BH, Glenthoj BY. Selective attention and mismatch negativity in antipsychotic-naïve, first-episode schizophrenia patients before and after six months of antipsychotic monotherapy. Psychol Med (2017) 47:2155–65. doi:10.1017/S0033291717000599
16. Madsen GF, Bilenberg N, Jepsen JR, Glenthoj B, Cantio C, Oranje B. Normal P50 gating in children with autism, yet attenuated P50 amplitude in the Asperger subcategory. Autism Res (2015) 8(4):371–8. doi:10.1002/aur.1452
17. Hardstone R, Poil SS, Schiavone G, Jansen R, Nikulin VV, Mansvelder HD, et al. Detrended fluctuation analysis: a scale-free view on neuronal oscillations. Front Physiol (2012) 3:450. doi:10.3389/fphys.2012.00450
19. Rydkjaer J, Mollegaard Jepsen JR, Pagsberg AK, Fagerlund B, Glenthoj BY, Oranje B. Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD. Psychol Med (2017) 47(2):377–88. doi:10.1017/S0033291716002518
20. Poil SS, Hardstone R, Mansvelder HD, Linkenkaer-Hansen K. Critical-state dynamics of avalanches and oscillations jointly emerge from balanced excitation/inhibition in neuronal networks. J Neurosci (2012) 32(29):9817–23. doi:10.1523/JNEUROSCI.5990-11.2012
21. Poil SS, Jansen R, van Aerde K, Timmerman J, Brussaard AB, Mansvelder HD, et al. Fast network oscillations in vitro exhibit a slow decay of temporal auto-correlations. Eur J Neurosci (2011) 34(3):394–403. doi:10.1111/j.1460-9568.2011.07748.x
22. Montez T, Poil SS, Jones BF, Manshanden I, Verbunt JP, van Dijk BW, et al. Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. Proc Natl Acad Sci U S A (2009) 106(5):1614–9. doi:10.1073/pnas.0811699106
23. Nikulin VV, Jonsson EG, Brismar T. Attenuation of long-range temporal correlations in the amplitude dynamics of alpha and beta neuronal oscillations in patients with schizophrenia. Neuroimage (2012) 61(1):162–9. doi:10.1016/j.neuroimage.2012.03.008
Keywords: tuberous sclerosis complex, tuberous sclerosis complex-associated neuropsychiatric disorders, hyperexcitability, bumetanide, electroencephalography, event-related potentials
Citation: Vlaskamp C, Poil S-S, Jansen F, Linkenkaer-Hansen K, Durston S, Oranje B and Bruining H (2017) Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex. Front. Neurol. 8:469. doi: 10.3389/fneur.2017.00469
Received: 16 June 2017; Accepted: 25 August 2017;
Published: 08 September 2017
Edited by:Con Stough, Swinburne University of Technology, Australia
Reviewed by:Thomas Heinbockel, Howard University, United States
Stephen Morairty, SRI International, United States
Copyright: © 2017 Vlaskamp, Poil, Jansen, Linkenkaer-Hansen, Durston, Oranje and Bruining. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chantal Vlaskamp, firstname.lastname@example.org